Translational Research Institute

Translational Research Institute
Published 9-11-2013
  • Laboratory

    Photo by Christopher Frederick Jones

  • Atrium

    Photo by Christopher Frederick Jones

Translational Research Institute (TRI) is a joint venture between The University of Queensland Diamantina Institute, Queensland University of Technology’s Institute of Health and Biomedical Innovation, Mater Research, and the Princess Alexandra Hospital Centres for Health Research.

TRI represents four leading medical research institutes with the joint aim of translating the findings of basic biomedical research into better patient outcomes. The Institute allows—for the first time in Australia—biopharmaceuticals and treatments to be discovered, produced, clinically tested, and manufactured in one location.

Bringing together a number of existing institutes engenders a sense of community within TRI and encourages integration and the sharing of ideas and knowledge across all staff.

The full TRI project includes three components: the $199 million Institute; Bio-Pharmaceuticals Australia (BPA), which is a $41.5 million pharmaceutical manufacturing scaleup facility located on the site; and a refurbishment within the adjacent hospital building for clinical trials associated with the research undertaken in TRI. An Australian first, TRI represents the turnkey “bench-to-bedside” mode of progressing scientific research right through to clinical application. 

TRI itself is conceived as a series of interconnected places for research.  From the intimate to the expansive, the building acknowledges the diverse communities that make up TRI and enables both the intensity of scientific research and a range of opportunities for collaboration.  Typically strictly functional, the laboratory is, in this instance, elevated as a very human place for people to work at the highest level in the pursuit of scientific discovery.  Careful fabrication of the building itself gives a finessed presence to the scientists’ pursuits.

The 420,000-sf, eight-story building is designed to house more than 650 researchers, with an additional 200 support staff.

TRI’s collaborative research expertise across common and serious diseases such as cancers, diabetes, inflammatory diseases, HIV, malaria, bone and joint diseases, obesity, and childhood illnesses will have a direct impact on improved public health and enhanced preventative treatments for the community.

Project Data
Project Type: 
New Construction
Completion Date: 
December, 2012
Location: 
Woolloongabba, QLD, Australia
Delivery Method: 
Lump Sum
Project GSF: 
419,792
Construction Cost: 
$240,500,000USD
Building Descriptors: 
Atrium
Biocontainment
Biomedical
Laboratory: Biomedical Research
Laboratory: R+D
Laboratory: Research
R+D
Research: Biomedical
Research: Pharmaceutical
Translational Research
Organizations
Architect
Donovan Hill Architects
Associate Architect
Davis Langdon
Cost Planner
Aurecon
Structural Engineer
Aurecon
Façade Engineer
Hawkins Jenkins Ross (HJR)
Mechanical Engineer
MultiTech Solutions (MTS)
Mechanical Engineer
Aurecon
Electrical Engineer
Wilson Landscape Architects
Landscape Architect
Donovan Hill Architects
Associate Landscape Architect
AECOM
Environmental
Exova Warrington Fire
Fire Engineer
Cundall
Vertical Transportation Engineer
ASK Consulting Engineers
Acoustical
Certis
Building Certifier
Watpac Construction Pty Ltd
Builder
Wilkore Pty Ltd
PC-3 Containment Area
Biotechnique Pty Ltd
Dagard Panels
Beckman
Centrifuges (floor, bench top, high-speed, and high-capacity)
Thermo Fisher Scientific
Cytocentrifuge
ESCO
Biological Safety Cabinets
ESCO
Laminar Flow Cabinet
ESCO
Cytotoxic Cabinets
Perkin Elmer
Cell Harvester
Nikon
Spinning Disc Confocal Microscope
Olympus
Confocal Microscope
Olympus
Epifluoresence Microscope
Olympus
Slide Scanner
NanoDrop
Microlitre Spectrophotometer
Tomy
Autoclave Lab